Richard Byworth suggests that Bitcoin is likely to rise again soon, linking this to seller exhaustion in the market. However, he warns that using covered-call strategies during a rally could lead to substantial losses for holders. Byworth also highlights basis trades backed by Bitcoin as a safer way to earn dollar returns with lower volatility and less dependence on Bitcoin's price movements. This insight is important for investors seeking yield while managing risk in Bitcoin holdings.
The story on Bitcoin and seller exhaustion provides context for readers interested in cryptocurrency trends. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 19, 2026 23:31 WIB: out of 50 priced assets, 41 rose and 8 fell. Notable movers include SUSHI at Rp3.913 with a 4.11% increase and a Pluang order activity of 14% Sell / 86% Buy, BAT at Rp3.270 with a 3.95% rise and 7% Sell / 93% Buy, and LTC at Rp1.080.951 with a 3.82% gain and 19% Sell / 81% Buy.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
